KO Client Watchmaker Genomics Raises $40M Series A Round
- KO Firm
- June 13, 2022
KO client Watchmaker Genomics, a life sciences company specializing in the development of high-stringency applications focused on the reading, writing and editing of DNA and RNA, has raised $40M to expand its clinical sequencing product offerings.
Founded in 2019, Watchmaker established an enzyme engineering technology platform that leverages recent advances in computational design and directed evolution.
With this Series A round of financing, Watchmaker plans to accelerate investment in its protein engineering platform to deliver a suite of new products that address the demands of clinical sequencing and support emerging applications in a single-cell analysis, epigenetics and cell-free DNA. The company will also expand commercial channels and manufacturing capacity to make these product solutions more broadly accessible to the life sciences and genomics communities.
“The additional financing will enable Watchmaker to more quickly scale our organization to meet the explosive demands of the genomics industry and help to further realize our vision of more personalized medicine and improved human health,” said Trey Foskett, CEO and Co-Founder of Watchmaker Genomics.
Read more on the funding.